Sugi Predict

Sugi Predict / Compounds / SCHEMBL3274432

SCHEMBL3274432

SCHEMBL3274432

CCOC(=O)c1oc(C)nc1C

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 5/20 0.47
▸ CYP1A2 P05177 1/20 0.43
▸ PDE4D Q08499 1/20 0.42
▸ FBP1 P09467 1/20 0.42
▸ ALDH1A1 P00352 5/20 0.41
▸ SMN1; SMN2 Q16637 5/20 0.41
▸ LMNA P02545 4/20 0.41
▸ TSHR P16473 1/20 0.41
▸ KDM4E B2RXH2 3/20 0.41
▸ NPC1 O15118 2/20 0.41
▸ RAB9A P51151 2/20 0.41
▸ AHR P35869 1/20 0.41
▸ L3MBTL1 Q9Y468 1/20 0.41
▸ HSD17B10 Q99714 3/20 0.40
▸ HTT P42858 2/20 0.40
▸ HDAC4 P56524 1/20 0.40
▸ HDAC6 Q9UBN7 1/20 0.40
▸ MEN1 O00255 1/20 0.40
▸ USP2 O75604 1/20 0.40
▸ POLB P06746 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11164366 0.81 TARBP2 (0.42) MAPTCYP1A2PDE4DFBP1ALDH1A1
SCHEMBL781841 0.81 FBP1 (0.56) MAPTCYP1A2FBP1ALDH1A1SMN1; SMN2
SCHEMBL779128 0.81 TARBP2 (0.42) MAPTCYP1A2PDE4DFBP1ALDH1A1
SCHEMBL6177971 0.81 CYP1A2 (0.41) MAPTCYP1A2FBP1ALDH1A1LMNA
SCHEMBL9750715 0.81 CYP1A2 (0.41) MAPTCYP1A2PDE4DFBP1ALDH1A1
SCHEMBL25369787 0.80 CYP1A2 (0.40) MAPTCYP1A2PDE4DFBP1ALDH1A1
SCHEMBL9207367 0.80 TARBP2 (0.44) CYP1A2FBP1ALDH1A1KDM4EHSD17B10
SCHEMBL408193 0.80 ALDH1A1 (0.53) MAPTALDH1A1SMN1; SMN2LMNATSHR
SCHEMBL12324413 0.79 CYP1A2 (0.39) MAPTCYP1A2FBP1ALDH1A1LMNA
SCHEMBL12323577 0.79 PLK1 (0.44) MAPTCYP1A2FBP1ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114478423-B Preparation method of 2, 4-dimethyl oxazole-5-formic acid 八叶草健康产业研究院(厦门)有限公司 2024-07-12 — — CN claimed
CN-114478423-A Preparation method of 2, 4-dimethyloxazole-5-formic acid 八叶草健康产业研究院(厦门)有限公司 2022-05-13 — — CN claimed
CN-114478423-B Preparation method of 2, 4-dimethyl oxazole-5-formic acid 八叶草健康产业研究院(厦门)有限公司 2024-07-12 — — CN disclosed
CN-114478423-A Preparation method of 2, 4-dimethyloxazole-5-formic acid 八叶草健康产业研究院(厦门)有限公司 2022-05-13 — — CN disclosed
CN-114478423-A Preparation method of 2, 4-dimethyloxazole-5-formic acid 八叶草健康产业研究院(厦门)有限公司 2022-05-13 — — CN disclosed
US-20140315881-A1 COMPOUNDS AND METHODS TEMPERO PHARMACEUTICALS, INC. 2014-10-23 — — US disclosed
US-8779086-B2 Electrochromic material and a method for producing the same KURARAY CO., LTD. (JP) 2014-07-15 — — US disclosed
US-8779086-B2 Electrochromic material and a method for producing the same KURARAY CO., LTD. (JP) 2014-07-15 — — US disclosed
US-8779086-B2 Electrochromic material and a method for producing the same KURARAY CO., LTD. (JP) 2014-07-15 — — US disclosed
EP-2736330-A1 COMPOUNDS AND METHODS Tempero Pharmaceuticals, Inc. (US) 2014-06-04 — — EP disclosed
WO-2013019682-A1 COMPOUNDS AND METHODS TEMPERO PHARMACEUTICALS, INC. (US) 2013-02-07 — — WO disclosed
US-20070032529-A1 Pyrazole compounds and their use as antidiabetes agents JAPAN TOBACCO INC. (JP) 2007-02-08 — — US disclosed
US-20060019965-A1 Gonadotropin releasing hormone receptor antagonists WYETH (US) 2006-01-26 — — US disclosed
WO-2006009734-A1 GONADOTROPIN RELEASING HORMONE RECEPTOR ANTAGONISTS WYETH (US) 2006-01-26 — — WO disclosed
US-20050239797-A1 Isoquinoline and quinazoline derivatives having a combined 5HT1A, 5HT1B, and 5HT1D receptor activity SMITHKLINE BEECHAM, PLC 2005-10-27 — — US disclosed
EP-1228043-B1 ISOQUINOLINE AND QUINAZOLINE DEIVATIVES HAVING A COMBINED 5HT1A, 5HT1B AND 5HT1D RECEPTOR ACTIVITY SMITHKLINE BEECHAM PLC (GB) 2005-01-12 — — EP disclosed
EP-1228043-A1 ISOQUINOLINE AND QUINAZOLINE DEIVATIVES HAVING A COMBINED 5HT1A, 5HT1B AND 5HT1D RECEPTOR ACTIVITY SMITHKLINE BEECHAM PLC (GB) 2002-08-07 — — EP disclosed
WO-2001032626-A1 ISOQUINOLINE AND QUINAZOLINE DERIVATIVES HAVING A COMBINED 5HT1A, 5HT1B AND 5HT1D RECEPTOR ACTIVITY SMITHKLINE BEECHAM P.L.C. (GB) 2001-05-10 — — WO disclosed
US-5049698-A Chlorination EASTMAN KODAK COMPANY (US) 1991-09-17 — — US disclosed
EP-0034481-A1 2-Methyl-5-thiazole-methylamine and carboxamide derivatives Grigg, Ronald Ernest (GB) 1981-08-26 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060019965-A1 Gonadotropin releasing hormone receptor antagonists GNRHR, GHRHR, LHCGR MAPT 2569/4885CYP1A2 4039/4885PDE4D 1744/4885
US-20070032529-A1 Pyrazole compounds and their use as antidiabetes agents PYGL, GYS2, AGL MAPT 4621/4885CYP1A2 683/4885PDE4D 1945/4885
US-20140315881-A1 COMPOUNDS AND METHODS RORC, RORB, RORA MAPT 3084/4885CYP1A2 501/4885PDE4D 1624/4885
US-20050239797-A1 Isoquinoline and quinazoline derivatives having a combined 5HT1A, 5HT1B, and 5HT1D receptor activity HTR1B, HTR1A, HTR1D MAPT 1700/4885CYP1A2 161/4885PDE4D 412/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.